

Detailed Table of Contents

Foreword	vii
Preface to the Third Edition	ix
Preface to the Second Edition	xiii
Preface to the First Edition	xvii
About the Authors	xxv
Summary Table of Contents.....	xxxv
Chapter 1 An Introduction to Health Care Fraud and Abuse.....	1
I. Introduction	2
A. The Potential Risks Throughout the Health Care Industry.....	3
1. Notable Cases and Settlements.....	6
2. Notable Defense Victories	24
B. Exposure for Attorneys	26
C. Likelihood of Increased Enforcement Efforts in the Future	32
1. Pharmaceuticals	36
2. Hospitals/Health Systems	38
3. Other Providers/Suppliers.....	40
4. Medicare Part D.....	40
5. State Enforcement	42
6. Private Enforcement	45
7. RACs, MEDICs, and ZPICs	46
8. Disclosure of Physician Relationships With Drug and Device Vendors	49
II. The Federal Fraud and Abuse Laws.....	51
A. The Anti-Kickback Statute	52
1. The Prohibitions	52
2. Exceptions and Safe Harbors.....	53
3. Special Fraud Alerts and Special Advisory Bulletins.....	56
4. Office of Inspector General Advisory Opinions.....	59
5. Other Guidance.....	62
6. Enforcement	64
B. The Stark Law.....	66
1. The Prohibitions	66
2. The Exceptions	69
3. Available Guidance: Preambles, Advisory Opinions, and Court Decisions	71

4. Specialty Hospitals	74
5. Enforcement	76
C. False Claims Statutes	82
1. The False Claims Act.....	82
2. Other Statutes Prohibiting False Claims.....	88
D. Civil Monetary Penalties	89
1. The Prohibitions	89
2. Beneficiary Inducement.....	93
3. Gainsharing.....	97
4. Drug Product and Price Reporting	99
5. CMP Enforcement.....	99
E. Exclusion Authorities.....	100
1. Mandatory Exclusion.....	100
2. Permissive Exclusion.....	101
3. Special Advisory Bulletin on Exclusion.....	103
4. Exclusion of Corporate Officers	105
F. Federal All-Payor Statutes	106
G. Screening Procedures for Providers and Suppliers	107
III. State Laws	108
IV. Other Resources	112
A. Compliance Program Guidance	113
B. The OIG Work Plans	115
C. The OIG Semiannual Reports.....	118
D. Enforcement Resources	118
1. The OIG’s Provider Self-Disclosure Protocol	118
2. The Inspector General’s Open Letter on the CIA Process	120
3. The Self-Referral (Stark Law) Disclosure Protocol	121
E. Other Guidance.....	122
F. Miscellaneous	124
V. Conclusion	125
Chapter 2 Federal Physician Self-Referral Restrictions	127
I. Introduction.....	131
II. Historical Background	132
A. Legislative History.....	132
B. Regulatory History.....	133
1. Sanctions.....	133
2. Stark I	134
3. Stark II Proposed Rule.....	134
4. Stark II Final Rules.....	134
a. Phases I and II	134
b. Phase III Final Rule.....	135
c. CMS’s Approach to Drafting the Final Rules	135
5. EHR Donation Final Rule	136
6. Annual Rulemaking Cycle	136
C. Affordable Care Act (ACA).....	136
D. Effective Dates.....	137
E. Interaction With State Self-Referral Laws	139
III. General Prohibition and Key Statutory Terms	139
A. The General Prohibition	139
B. Key Statutory Terms	140
1. Referral.....	140

2.	Entity	142
a.	Revised Definition of “Entity”	142
b.	Performing a DHS	143
3.	Financial Relationship	144
4.	Ownership or Investment Interest	144
a.	Direct Ownership or Investment Interest	144
b.	Indirect Ownership or Investment Interest	145
5.	Compensation Arrangement	146
6.	Remuneration	147
7.	Knowledge Standard	148
C.	Temporary Noncompliance Exception	149
D.	Alternative Method of Compliance With Signature Requirement	150
IV.	Designated Health Services	151
A.	Listed Designated Health Services	151
B.	General Principles	151
C.	Radiology and Certain Other Imaging Services	152
D.	Outpatient Prescription Drugs	152
E.	Inpatient and Outpatient Hospital Services	153
V.	Exceptions Related to Physician Compensation	153
A.	Introduction	153
B.	Volume or Value, Other Business Generated, and Set in Advance	154
1.	Volume or Value of Referrals	154
2.	Other Business Generated	157
3.	Set-in-Advance Test	158
a.	Percentage-Based Compensation and Productivity Bonuses	158
b.	Specific Formula	159
C.	Fair Market Value Definition	160
D.	Commercially Reasonable	163
E.	Directed Referrals	163
F.	Compensation to Physician Employees	163
1.	The Bona Fide Employment Exception	163
2.	Leased Employees	164
G.	Compensation to Physician Independent Contractors and Physicians in the Group	164
VI.	Indirect Compensation Definition and Exception	164
A.	Definitions	165
1.	Unbroken Chain Test	165
2.	Volume or Value or Other Business Generated Test	165
3.	Knowledge	166
B.	Exception for Indirect Compensation Arrangements	166
C.	The Physician “Stand in the Shoes” Rule	167
D.	Physician Organization	171
E.	The Grandfathering Provision	171
F.	DHS Entity “Stand in the Shoes”	172
VII.	Definition of Group Practice and Exceptions for In-Office Ancillary Services and Physician Services	173
A.	Group Practice Definition	173
1.	Single Legal Entity	174
2.	Members of the Group	175
3.	Physician in the Group Practice	175
4.	The “Full Range of Services” Test	176

5.	The “Substantially All” Test	176
6.	The Unified Business Test	178
7.	Compensation: Profit Shares and Productivity Bonuses	179
8.	Group Practice Productivity Bonuses Related to “Incident to” Services and Supplies	180
9.	Foundation-Model Group Practices.....	181
B.	In-Office Ancillary Services Exception	182
1.	Scope of DHS That Can Be In-Office Ancillary Services.....	182
2.	Building Requirements	183
a.	Centralized Building	183
b.	Same Building	183
i.	Shared Space in “Same Building”	186
3.	Direct Supervision	186
4.	Billing Requirements.....	187
5.	Clarification of Interplay of In-Office Ancillary Services Exception and Reassignment and Purchased Diagnostic Tests	188
6.	Disclosure Requirements for Certain Imaging Services	188
C.	Exception for Physician Services	189
VIII.	Managed Care Prepaid Plans and Risk-Sharing Exceptions.....	190
A.	The Prepaid Plan Exception.....	190
B.	Risk-Sharing Compensation Arrangements Exception	191
IX.	Exception for Academic Medical Centers	192
A.	Teaching Hospital	193
B.	Referring Physician	193
C.	Compensation to Physicians in Academic Medical Centers.....	194
D.	Faculty Practice Plans	195
E.	Other AMC Exception Requirements	195
X.	Other Exceptions Related to Both Ownership and Compensation	196
A.	Implants Furnished in Ambulatory Surgery Centers	196
B.	EPO and Other Dialysis-Related Outpatient Prescription Drugs	197
C.	Preventive Screening Tests, Vaccinations, and Immunizations	197
D.	Eyeglasses and Contact Lenses Following Cataract Surgery	198
E.	Intra-Family Referrals in Rural Areas	198
XI.	Ownership and Investment Interest Exceptions	200
A.	Publicly Traded Securities and Mutual Funds	200
B.	Specific Providers	201
1.	Hospital Ownership in Puerto Rico	201
2.	Rural Providers.....	201
3.	Hospital Ownership	202
a.	Specialty Hospital Moratorium	203
b.	ACA Limitations on Physician-Owned Hospitals.....	204
i.	Basic Restrictions.....	204
ii.	Expansion of Physician-Owned Hospitals	206
iii.	Timing Issues	207
c.	The Whole Hospital Exception and the 2011 OPFS Final Rule	207
d.	The Whole Hospital Exception and the 2012 OPFS Final Rule	209
XII.	Statutory Compensation Exceptions	210
A.	Rental of Office Space and Equipment.....	211
1.	Amendments	211
2.	Sharing Space or Equipment	212

3.	Holdover	213
4.	Early Termination	213
5.	Subleases	213
6.	“Per Click” or Percentage Leases	214
7.	Capital Leases	214
B.	Personal Service Arrangement Exception	214
1.	Termination	215
2.	Master List of Contracts	215
3.	“Furnishing Services”	216
4.	Physician Incentive Plans	216
5.	Amendments	216
C.	Physician Recruitment	217
1.	Providers Subject to the Rule	217
2.	Income Guarantees and Allocated Costs	218
3.	Unavailability of Other Exceptions	218
4.	Relocation Requirement	219
5.	Geographic Area Served by the Hospital	220
6.	Referral Considerations	220
7.	Seeding Arrangements	220
a.	Flow of Funds	221
b.	Overhead Payments	222
c.	Practice Restrictions	223
8.	Anti-Kickback Compliance	224
9.	Written Agreement Signed by All Parties	224
10.	Other Issues	224
D.	Isolated Transactions	225
E.	Remuneration Unrelated to the Provision of Designated Health Services	226
F.	Certain Group Practice Arrangements With Hospitals	227
G.	Payments by a Physician for Items and Services	228
XIII.	Compensation Exceptions Created by Regulation	229
A.	Introduction	229
B.	The FMV Exception (Phase I)	229
C.	Charitable Donations by Physicians (Phase II)	229
D.	Nonmonetary Compensation (Phase I)	230
E.	Medical Staff Incidental Benefits (Phase I)	231
F.	Compliance Training (Phase I)	232
G.	Referral Services and Obstetrical Malpractice Insurance Subsidies (Phase II)	233
H.	Professional Courtesy (Phase II)	233
I.	Retention Payments in Underserved Areas (Phase II)	234
J.	Community-Wide Health Information Systems (Phase II)	236
K.	Electronic Health Records Exception	236
XIV.	Application of Stark to State Medicaid Programs	238
XV.	Reporting Requirements and Sanctions	239
A.	Reporting Requirements	239
B.	Sanctions	241
C.	Burden of Proof	242
D.	Period of Disallowance	242
XVI.	Differences Between the Stark Law and the Federal Anti-Kickback Statute	243
XVII.	Stark Voluntary Self-Disclosure Protocol	245

XVIII. Stark Law Advisory Opinions.....	249
XIX. Shared Saving Program: Fraud and Abuse Waivers.....	251
XX. Conclusion	254

Chapter 3 The False Claims Act in Health Care Prosecutions: Application of the Substantive, Qui Tam, and Voluntary Disclosure Provisions	255
I. Introduction.....	258
II. Construction of the “False” and “Knowing” Elements of the False Claims Act and False Claims Act Damages	261
A. Falsity.....	262
1. Factual Falsity.....	264
2. Legally False Certification	264
a. Express False Certification.....	264
b. Implied False Certification.....	271
3. Cases in Which Courts Refused to Find That Defendant Submitted False or Fraudulent Claims or Statements	273
a. Literal Compliance.....	273
b. Nonobjective False Claims.....	274
B. The FCA “Knowing” Standard.....	277
1. Reckless Disregard	278
2. Deliberate Ignorance	280
3. Defenses Demonstrating Lack of Knowledge	283
a. Merely Negligent Conduct Does Not Result in Liability Under the FCA	285
b. The Government Cannot Predicate an FCA Action on Ambiguous Regulatory Guidance	290
c. Government Knowledge May Provide a Defense	291
d. The Defendants’ Reliance on Sound Legal Theory Negates an Inference of Fraud	294
C. Materiality.....	303
1. Government Awareness of the Alleged Falsity.....	303
2. Whether a Statement Could Have Influenced the Government’s Funding Decision.....	306
D. FCA Damages and Civil Penalties	308
1. Kickbacks and Regulatory Violations	308
2. Determination of Number of Civil Penalties	313
a. CMS-1500 Form.....	315
b. UB-92 Forms and Cost Reports	316
c. Dollar Amount of Civil Penalties Assessed Against Defendant	319
3. Constitutional Limitations on Civil Penalties	320
a. The Eighth Amendment	321
i. Extent and Harm of Defendant’s FCA Violations.....	322
ii. Comparable Penalties	323
iii. Class for Whom the FCA Was Principally Designed ...	324
III. Preempting FCA Actions: The Office of Inspector General’s Voluntary Disclosure Program.....	324
A. The Voluntary Disclosure Process	324
B. Benefits and Risks of Submitting a Self-Disclosure.....	325
1. Risks of Disclosure.....	325
2. Incentives for Disclosure	335

IV. Congress’s 2009 Revisions to the False Claims Act	336
A. Legislative History: The 1986 Amendments to the FCA.....	337
B. Post-1986 Case Law	339
1. The Link Between Claims and Presentment: <i>Totten</i> and <i>Allison Engine</i>	339
a. The D.C. Circuit’s Ruling in <i>Totten</i>	339
b. The Supreme Court’s Decision in <i>Allison Engine</i>	340
2. Reverse False Claims Case Law Developments	342
3. Statute of Limitations Case Law Developments	343
4. Whistleblower Retaliation Case Law Developments	343
C. Congress’s 2009 FCA Amendments	344
1. The Senate’s FCA Amendments	344
a. February 5, 2009, S. 386	344
b. DOJ’s February 25, 2009, Letter	346
c. Senate Judiciary Committee Report (March 2009)	350
d. April 22, 2009, Floor Statements	355
2. The House’s 2009 FCA Amendments (May 6, 2009)	359
a. Revisions to the Whistleblower Retaliation Provision	360
b. Statute of Limitations Provision.....	360
c. State Service Provision.....	361
d. Civil Investigative Demands.....	361
3. Expansion and Contraction of the FCA Resulting From the 2009 Amendments	363
a. Revisions to Subsections (a)(1)–(a)(2) (False Claims and Statements) and the Definition of “Claim”	363
b. Revisions to Subsection (a)(3) (Conspiracy)	364
c. Revisions to Subsection (a)(7) (Reverse False Claims)	364
d. Statute of Limitations	365
e. Whistleblower Retaliation.....	365
f. Projected Impact.....	365
V. The 2010 Amendments to the False Claims Act.....	366
A. Amendments to the Public Disclosure Bar.....	366
1. Congress’s Revisions That Appear to Embrace or Adopt Existing Precedent.....	368
a. Reference to Action or Claim.....	368
b. Eliminate “Based Upon” Language and Replace With the Phrase “Dismiss an Action or Claim ... if Substantially the Same Allegations or Transactions ... Were Publicly Disclosed”.....	369
c. Retention of News Media as a Trigger to the Public Disclosure Bar.....	375
d. One Alternate Element to Satisfy the Original Source Provision Is That the Relator Qualify as a True Whistleblower by Disclosing the Information to the Government Before the Public Disclosure.....	376
e. A Second Alternate Element to Satisfy the Original Source Provision Is That the Relator Contribute Valuable Information to the Government That “Materially Adds to the Publicly Disclosed Allegations or Transactions”.....	377

2.	Material Revisions to Statute That May Deviate From Existing Precedent	381
a.	No Express Reference to Subsection (e)(4) Divesting a Court of Subject Matter Jurisdiction and DOJ's Authority to Oppose Dismissal	381
b.	Application to Only "Federal" Hearings, Reports, Audits, or Investigations.....	387
3.	Unresolved Interpretation Questions	387
a.	What Does It Mean to Be "Publicly" Disclosed?.....	387
b.	What Will Be the Impact of the Supreme Court's Decision in <i>Schindler Elevator</i> ?.....	388
c.	Are Disclosures to the Government Public Disclosures?.....	390
B.	Clarification of Reverse False Claims Provision	393
C.	Amendments to the FCA's Whistleblower Retaliation Provision.....	396
D.	Amendment Declaring a Claim Paid as a Result of Kickback to Be a False Claim.....	397
VI.	Conclusion	399
Chapter 4	Practical Considerations for Defending Health Care Fraud and Abuse Cases	401
I.	The Evolving Nature of Health Care Fraud and Abuse Enforcement.....	404
A.	The Early Days	404
B.	Medicare and Medicaid	404
C.	The Late 1970s and 1980s	406
D.	Deregulation.....	406
E.	Office of Inspector General	408
F.	The <i>Hanlester Case</i>	409
G.	Modern Trends.....	409
H.	The Patient Protection and Affordable Care Act (ACA)	410
1.	Accountable Care Organizations	411
II.	Sources of Health Care Fraud and Abuse Investigations	412
A.	Internal Sources	413
B.	External Sources	414
C.	Importance of Determining the Source of Disclosed Information	415
III.	Enforcement and Investigative Agencies	416
A.	Federal Enforcement Agencies.....	416
B.	State Enforcement and Investigative Agencies.....	418
C.	Private Enforcers.....	419
IV.	Enforcement Weapons	420
A.	Federal Criminal Laws.....	420
1.	General Criminal Laws.....	420
2.	Health Care–Specific Criminal Statutes	421
a.	Health Insurance Portability and Accountability Act of 1996 (HIPAA)	421
b.	Health Information Technology and Clinical Health Act (HITECH).....	422
c.	Patient Protection and Affordable Care Act of 2010 (ACA) and the Federal Anti-Kickback Statute Intent Standard	423
B.	State Criminal Laws.....	423
C.	Federal Civil Laws.....	424
1.	The Federal False Claims Act.....	424

2.	Patient Protection and Affordable Care Act of 2010 (ACA) and the FCA.....	425
a.	Anti-Kickback Violations and the FCA	425
b.	The Public Disclosure Bar.....	425
c.	Report and Return Requirement.....	426
d.	Payment Suspension	427
e.	Coordination of Integrity Efforts	428
D.	State Civil Remedies.....	428
E.	Federal Administrative Agency Remedies.....	430
1.	Limited Judicial Review	430
2.	Suspension of Payments	431
F.	State Administrative Agency Remedies.....	432
G.	Identifying the Remedy Threatened by the Enforcement Agency.....	433
V.	Health Care Principles Being Enforced	434
A.	Hierarchy	434
B.	Importance of Reviewing All the Rules.....	434
1.	Informal Guidelines.....	435
2.	Agency Adjudicative Decisions.....	436
3.	Other Pronouncements	437
C.	Impact of the Rules.....	437
D.	Private Party Interpretations, Practices, and Codes of Conduct	438
VI.	Government Investigatory Strategies	439
A.	Overview.....	439
B.	Enforcement Agency Interviews.....	440
C.	Document Production	442
VII.	Responding to an Investigation.....	443
A.	Understanding the Government's Interests.....	443
B.	Communicating With Enforcement Agents and Their Attorneys	444
C.	Explaining the Client's Position	445
D.	Position Papers.....	445
E.	The Context Concept	446
F.	Explaining Industry Terms and Practices	448
VIII.	Impact of Investigations	450
A.	Timing.....	450
B.	Publicity.....	450
C.	Effect on Business	451
D.	Cash Flow Consequences	451
E.	Suing Government Officials for Reckless Investigations and Related Actions.....	452
IX.	Settlement Considerations	453
A.	Collateral Consequences.....	453
B.	Binding the Government.....	454
C.	Settlement Goals.....	455
D.	Life After a Settlement.....	455
X.	Litigation Defense Strategies.....	456
A.	Importance of the Fundamentals	456
1.	Necessity of Prohibited Act or Omission	456
2.	Necessity of Wrongful Intent	457
3.	Necessity of Agency Authority to Act	460
B.	Other Practical Defense Concepts	461
1.	Stressing the Facts	461
2.	Burden of Proof Requirements.....	461

3.	Credibility of Defendant.....	462
4.	Limited Judicial Review.....	462
XI.	Current Enforcement Priorities.....	463
A.	Historic Trends in Health Care Fraud Prosecution.....	463
B.	Focus Areas for OIG Investigation and Enforcement.....	465
C.	Noteworthy Settlements Since 2010.....	469
XII.	Enforcement Actions Involving Pharmaceuticals.....	472
A.	Introduction.....	472
B.	Enforcement Actions Involving Pricing Methodologies.....	473
1.	Price Inflation Through Average Wholesale Price Data.....	473
2.	Medicaid Drug Rebate Program.....	476
C.	Illegal Marketing.....	478
1.	Kickbacks.....	478
2.	Drug Switching.....	482
3.	Marketing Off-Label Uses.....	483
4.	Free Samples.....	490
D.	Defense Strategies.....	492
1.	Federal False Claims Act.....	492
a.	Government Knowledge of Pricing Scheme.....	492
b.	Challenging Scienter.....	493
c.	Challenging Causation.....	495
2.	Anti-Kickback Statute.....	496
a.	Kickbacks as False Claims: Lack of Certification.....	496
b.	Statutory Exception and Safe Harbor Protection: Discounts and Educational Grants.....	497
E.	Class Action Lawsuits on Behalf of Private Payors and Patients.....	498
F.	Counterfeit Drugs, Illegal Wholesaling, and Internet Pharmacies.....	498
G.	Laws Empowering Enforcement Agencies.....	498
H.	Conclusion.....	501
XIII.	The Intersection of the Stark Law and the False Claims Act.....	501
A.	Introduction.....	501
B.	Basis for Liability.....	502
C.	Litigation Involving the Stark Law and the FCA.....	503
D.	Defense Strategies.....	507
E.	Conclusion.....	508
XIV.	Emerging Issues: Sarbanes-Oxley and the Era of Corporate Responsibility.....	509
A.	Relevant Provisions of the Sarbanes-Oxley Act.....	509
B.	Litigation.....	510
XV.	Conclusion.....	511
 Chapter 5 Legal Issues Surrounding Hospital and Physician Relationships.....		 513
I.	Background on the Nature of Relationships Between Hospitals and Physicians and the Factors Affecting Those Relationships.....	515
II.	Legal Issues.....	517
III.	Relationships With Physicians Who Are Members of the Voluntary Medical Staff.....	521
A.	Medical Staff Membership.....	521
1.	Exclusive Contracts.....	522
2.	Economic Credentialing.....	522
a.	Anti-Kickback Issues.....	525

b. State Issues	525
B. Credential Review and Corrective Action	526
1. Verification of Credentials and Checking Available Databases ...	526
2. Physician Malpractice Insurance	527
3. Hospital Duty to Deal With Problem Practitioners	527
C. Corrective Action Under the Medical Staff Bylaws	531
D. Physician Attestation of Accuracy of Medicare Diagnoses	533
E. Physician Coverage of the Emergency Room	534
1. Reimbursement	535
2. Corporate Practice of Medicine Prohibitions	538
F. Perquisites for Members of the Medical Staff	538
1. Nonmonetary Compensation	539
2. Medical Staff Incidental Benefits	539
3. Professional Courtesy	541
4. Compliance Training	542
G. Donations of Health Information Technology	542
1. Community-Wide Health Information Systems Exception	542
2. Electronic Prescribing Exception	544
3. Electronic Health Records Exception	545
4. HITECH Act	547
H. Medicare Prohibition on Unbundling	547
I. Physician Use of Hospital Clinic Space	549
IV. Contractual Relationships With Physicians	550
A. Generally Applicable Limitations Arising From Tax-Exempt Status Can Be the Basis for Intermediate Sanctions Under the Internal Revenue Code	550
1. Definition of “Disqualified Persons”	551
2. Definition of “Reasonable Compensation”	553
3. Rebuttable Presumption That a Transaction Is Not an Excess Benefit	554
4. Rules for Revenue-Sharing Transactions	554
B. Lease of Space	555
1. Clarification of “Fair Rental Value”	558
C. Lease of Equipment	560
D. Medical Director Agreements	562
E. Employing and Contracting With Physicians for the Provision of Patient Care Services	565
1. Federal Compliance Issues	565
2. State Corporate Practice of Medicine Prohibitions	569
3. Medicare and Medicaid Prohibitions on the Reassignment of Revenue	571
F. Hospital-Based Physicians	573
1. Exclusivity	573
2. Anti-Kickback and Stark Issues	574
3. False Claims Issues	574
G. Discounts on Reference Laboratory Services	576
H. Practice Management Services Furnished by Hospitals to Physicians	577
I. Academic Medical Centers	578
1. Stark Issues	579
2. Anti-Kickback Issues	581
J. Gainsharing	582

- 1. Civil Monetary Penalties for Improper Incentive Plans 583
- 2. Gainsharing Within Managed Care 590
- 3. Stark Issues 591
- 4. Anti-Kickback Issues 593
- 5. Tax-Exempt Issues 596
- K. Physician Recruitment 597
 - 1. Tax-Exempt Issues 598
 - 2. Anti-Kickback Issues 601
 - 3. Stark Issues 606
- L. Physician Retention 609
 - 1. Stark Issues 609
 - 2. Provision of Malpractice Insurance Assistance 610
- V. Joint Ventures Between Hospitals and Physicians 612
 - A. Whole Hospital Ventures 613
 - 1. Stark Issues 614
 - 2. Anti-Kickback Issues 617
 - 3. Tax-Exempt Issues 619
 - B. Ambulatory Surgery Centers 621
 - 1. Stark Issues 622
 - 2. Federal Anti-Kickback Issues 623
 - C. “Under Arrangements” 630
 - 1. Provider-Based Requirements 630
 - 2. Anti-Kickback Issues 632
 - 3. Stark Issues 633
 - D. Physician-Hospital Organizations 634
 - 1. Capital Requirements and the Need to Avoid Hospital
Subsidization of Physician Members 634
 - 2. Antitrust Issues 635
 - 3. Business of Insurance 637
 - E. Service Line Leases 637
 - 1. Stark Issues 637
 - 2. Anti-Kickback Issues 638
 - 3. Anti-Markup Issues 640
 - F. Acquisition of Physician Practices 641
 - G. Clinical Co-Management 644
 - H. Accountable Care Organizations 645

**Chapter 6 Care Fraud and Abuse: Risk Areas for Government
Program Participants 651**

- I. Introduction 653
 - A. Government-Funded Managed Care Programs and the Enforcement
Environment 653
 - B. Medicare Managed Care 654
- II. Compliance Programs in Managed Care Organizations 656
 - A. Medicare Advantage Organizations 656
 - 1. 2007 CMS Final Rule 656
 - 2. 2010 CMS Guidance—Seven Required Elements 657
 - 3. 2012 OIG Recommendations and CMS Guidance 660
 - 4. The 1999 OIG Guidance for Medicare+Choice—Still
Relevant 661
 - a. Standards, Policies, and Procedures 661
 - i. Marketing Materials and Personnel 662

ii.	Selective Marketing and Enrollment.....	663
iii.	Disenrollment.....	664
iv.	Underutilization and Quality of Care.....	664
v.	Data Collection and Submission Processes.....	664
vi.	Anti-Kickback Statute and Other Inducements.....	665
vii.	Emergency Services.....	666
b.	Record Retention.....	666
c.	Compliance as Part of Employee Evaluation.....	667
d.	Subcontractor Compliance.....	667
e.	Compliance Officer.....	667
f.	The Compliance Committee.....	668
g.	Compliance Training.....	668
h.	Effective Lines of Communication.....	668
i.	Auditing and Monitoring.....	669
j.	Discipline.....	669
k.	Corrective Action.....	669
B.	Medicare Part D.....	670
C.	The Deficit Reduction Act.....	676
III.	Areas of Government Review, Monitoring, and Audit.....	677
A.	Centers for Medicare and Medicaid Services.....	677
1.	Audits.....	677
2.	Marketing.....	678
3.	Risk Adjustment Validation.....	683
B.	The OIG Work Plans.....	685
1.	Medicare Advantage.....	685
2.	Medicare Part D.....	686
3.	Medicaid Managed Care.....	687
IV.	Enforcement Actions.....	689
A.	Medicare.....	689
1.	Claims Processing and Coverage Determinations.....	689
2.	Risk Adjustment.....	689
3.	Marketing and Anti-Kickback Violations.....	690
B.	Medicaid.....	691
1.	Cherry-Picking.....	691
2.	Inflated Medical Claims Expense.....	691
3.	Failure to Provide Mandated Care.....	692
4.	Marketing Violations.....	693
5.	Overpayments.....	693
6.	Enforcement Trends.....	694
C.	Federal Employees Health Benefits Program.....	694
1.	Overview.....	694
2.	Enforcement Actions Against Managed Care Organizations in the Federal Employees Health Benefits Program.....	695
V.	Potential False Claims Act and False Statement Liability Under Medicare Advantage, Medicare Part D, and Other Government Health Programs.....	696
A.	Culpable Parties.....	697
B.	Levels of Knowledge.....	697
C.	Definition of “Claim”.....	698
D.	Damages.....	699
E.	Liability for Submission of Certified Rate, Enrollment, and Encounter Data.....	701

1. Medicare Advantage Bid Submission.....	701
2. Part D.....	702
F. Medicare Secondary Payor Provisions	703
G. Reporting of Commissions and Fees Paid to Insurance Brokers and Agents	704
H. PBM Fraud and Abuse Issues	705
I. Other Statutes.....	707
VI. Managed Care Exceptions to the Anti-Kickback Statute.....	707
A. Negotiated Rulemaking	707
B. Capitated Managed Care Entity Safe Harbor	708
C. Risk-Sharing Safe Harbor	708
D. Some Common Elements of Both Safe Harbors	710
1. Health Care Items and Services.....	710
2. No Swapping or Shifting of Financial Burden	710
VII. Prompt Payment and Denial of Care Compliance Issues	711
A. Prompt Payment.....	711
B. Denial of Care.....	712
VIII. Increased State Enforcement Efforts.....	714
IX. Conclusion	715
Chapter 7 Corporate Compliance Programs.....	717
I. Introduction.....	721
II. Benefits of a Corporate Compliance Program	724
A. Federal Sentencing Guidelines	724
1. Probation.....	725
2. Reduced Fines	727
3. Elements of an “Effective” Compliance Program	728
4. Implication of the Supreme Court’s <i>Booker</i> Decision on Corporate Compliance Programs	731
B. HHS Guidelines on Permissive Exclusion.....	733
C. FDA Guidelines for Recommending <i>Park</i> Doctrine Prosecutions	736
III. Elements of an Effective Compliance Program	737
A. General Criteria	737
B. Corporate Integrity Agreements and Deferred Prosecution Agreements	738
IV. Model Corporate Compliance Programs	740
A. Compliance Program Guidance for Hospitals	741
1. Hospital Risk Areas	745
a. Submission of Accurate Claims and Information.....	746
i. Outpatient Procedure Coding.....	746
ii. Admissions and Discharges	747
iii. Supplemental Payment Considerations.....	747
iv. Use of Information Technology	747
b. The Physician Self-Referral Law (Stark Law) and Federal Anti-Kickback Statute	748
i. Stark Law Compliance.....	748
ii. Anti-Kickback Compliance.....	749
c. Gainsharing Arrangements.....	751
d. EMTALA.....	751
e. Substandard Care.....	751
f. Relationships With Federal Health Care Beneficiaries	752
g. HIPAA Privacy and Security Rules	753

h.	Topics of General Interest to Hospitals	753
2.	Ensuring Compliance Program Effectiveness	753
a.	Developing a General Code of Conduct.....	753
b.	Regularly Reviewing Compliance Program Elements	754
i.	Designating a Compliance Officer and Compliance Committee	754
ii.	Developing Compliance Policies and Procedures.....	755
iii.	Developing Open Lines of Communication.....	755
iv.	Appropriate Training and Education.....	756
v.	Internal Monitoring and Auditing	756
vi.	Responding to Detected Deficiencies	757
vii.	Enforcing Disciplinary Standards	757
B.	Compliance Program Guidance for Clinical Laboratories	758
1.	Clinical Laboratory Risk Areas	758
a.	Medical Necessity	758
i.	Requisition Form.....	758
ii.	Notices.....	759
iii.	Physician Acknowledgements.....	759
iv.	Advanced Beneficiary Notices.....	759
v.	Test Utilization Monitoring.....	759
b.	Billing	760
i.	Selecting CPT or HCPCS Codes.....	760
ii.	Selecting ICD-9-CM Codes	760
iii.	Tests Covered by Claims for Reimbursement.....	760
iv.	Calculations.....	760
v.	Reflex Testing	760
vi.	Reliance on Standing Orders.....	760
c.	Marketing	761
d.	Prices Charged to Physicians	761
2.	Ensuring Compliance Program Effectiveness	761
a.	Dealing with Employees and Contractors	761
b.	Audits	762
c.	Investigations.....	762
C.	Compliance Program Guidance for the Durable Medical Equipment, Prosthetics, Orthotics, and Supply Industry	763
1.	DME Risk Areas.....	763
2.	Ensuring Compliance Program Effectiveness	765
a.	Compliance Officer Responsibilities.....	765
b.	Education and Training	765
i.	Claim Development and Billing Training	766
ii.	Sales and Marketing Training	766
iii.	Ongoing Education Responsibilities	766
c.	Hotline	766
d.	Auditing and Monitoring.....	766
e.	Corrective Action.....	767
D.	Compliance Program Guidance for Third-Party Medical Billing Companies	767
1.	Billing Company Risk Areas	768
2.	Reporting Provider Misconduct.....	769
E.	Compliance Program Guidance for Hospices.....	769
1.	Hospice Risk Areas.....	769
F.	Compliance Program Guidance for Nursing Facilities.....	771

1.	OIG Compliance Program Guidance for Nursing Facilities	771
a.	Nursing Facility Risk Areas	771
	i. Quality of Care.....	771
	ii. Residents’ Rights	772
	iii. Billing and Cost Reporting.....	772
	iv. Employee Screening.....	772
	v. Kickbacks, Inducements, and Self-Referrals	773
b.	Ensuring Compliance Program Effectiveness	774
	i. Auditing and Monitoring.....	774
	ii. Disciplinary Guidelines.....	774
	iii. Corrective Action	774
2.	OIG Supplemental Compliance Program Guidance for Nursing Facilities	774
a.	Quality-of-Care Risk Areas	775
	i. Sufficient Staffing	775
	ii. Comprehensive Resident Care Plans.....	775
	iii. Appropriate Use of Psychotropic Medications	776
	iv. Medication Management	776
	v. Resident Safety	777
b.	Submission of Accurate Claims Risk Areas	778
	i. Proper Reporting of Resident Case-Mix	778
	ii. Therapy Services	778
	iii. Screening for Excluded Individuals and Entities	779
	iv. Restorative and Personal Care Services	779
c.	The Federal Anti-Kickback Statute	780
	i. Free Goods and Services	781
	ii. Services Contracts	781
	iii. Discounts	782
	iv. Hospices	783
	v. Reserved Bed Arrangements	783
d.	Other Risk Areas	784
	i. Physician Self-Referrals	784
	ii. Anti-Supplementation	784
	iii. Medicare Part D	785
	iv. HIPAA Privacy and Security Rules.....	785
e.	An Ethical Culture	785
	i. Code of Conduct	785
	ii. Regular Review of Compliance Program Effectiveness	786
	iii. Communication to Decisionmakers	786
f.	Self-Reporting	786
3.	Affordable Care Act Requirements for Compliance and Ethics Programs.....	786
G.	Compliance Program Guidance for Medicare Advantage Organizations	788
1.	Compliance Program Guidance for Medicare+Choice Organizations Offering Coordinated Care Plans	788
a.	Risk Areas	788
2.	Regulatory Requirements for an Effective Compliance Program for Medicare Advantage Organizations	789
3.	Medicare Managed Care Manual Chapter 21—Compliance Program Guidelines	790

H.	Compliance Program Guidance for Individual and Small-Group Physician Practices	790
	1. Risk Areas for Physicians	791
	2. Other Helpful Resources for All Health Care Organizations	792
I.	Compliance Program Guidance for Home Health Agencies	792
	1. Home Health Agency Risk Areas	793
	a. Improper Joint Ventures	793
	b. Billing for Unallowable Costs of Home Health Coordination.....	793
	c. Unqualified or Unlicensed Personnel.....	793
	d. Falsified Plans of Care.....	794
	e. Improper Patient Solicitation Activities and High-Pressure Marketing	794
	f. Billing for Services to Patients Who Are Not Truly Homebound	794
	g. Billing for Visits to Patients Who Do Not Require a Qualifying Service.....	794
	h. Duplication of Services	795
	i. Willing Caregivers.....	795
J.	Compliance Program Guidance for Ambulance Suppliers	795
	1. Ambulance Risk Areas	795
	a. Medical Necessity and Upcoding.....	795
	b. Documentation, Billing, and Reporting	796
	c. Medicare Part A Payment for Services “Under Arrangements”.....	796
	d. Medicaid Requirements.....	796
	e. Arrangements With Patients and Other Providers.....	796
	f. Additional Risk Areas	796
	2. Making a Compliance Program Effective	797
	a. Auditing and Monitoring.....	797
K.	Compliance Program Guidance for Pharmaceutical Manufacturers	797
	1. Compliance Program Guidance for Pharmaceutical Manufacturers	797
	a. Compliance Program Elements	798
	b. Risk Areas for Drug (and Device) Companies	799
	i. Integrity of Data Used to Establish Reimbursement.....	799
	ii. Kickback and Other Illegal Remuneration.....	799
	iii. Risks Related to Purchasers	800
	(a) Discounts and Remuneration to Purchasers.....	800
	(b) Formularies and Formulary Support Services	802
	(c) Average Wholesale Price	803
	iv. Relationships With Physicians and Other Referral Sources	803
	v. Relationships With Sales Agents.....	806
	vi. Drug Samples	806
	2. Industry Guidance	806
	3. Medical School and Academic Medical Center Conflict of Interest Policies	807
L.	Draft Compliance Program Guidance for NIH Grant Recipients.....	808
	1. High-Risk Areas for NIH Grant Recipients.....	808
	a. Time and Effort Reporting	808

b.	Proper Allocation of Charges	809
c.	Reporting Financial Support from Other Sources.....	809
M.	Part D Compliance Program Guidelines.....	809
1.	Part D Program to Control Fraud, Waste, and Abuse (2006 Prescription Drug Benefit Manual Chapter 9).....	809
a.	Risk Areas	810
i.	Part D Plan Sponsors.....	810
ii.	PBMs.....	811
iii.	Pharmacies	811
iv.	Prescribers.....	812
v.	Wholesalers	812
vi.	Manufacturers	812
vii.	Medicare Beneficiaries.....	813
2.	Regulatory Requirements for an Effective Compliance Program for Part D Plan Sponsors.....	814
3.	Part D Compliance Program Guidelines (2012 Prescription Drug Benefit Manual Chapter 9).....	814
a.	Description of Compliance Program Elements.....	815
b.	Part D Sponsor Accountability and Oversight.....	820
N.	Accountable Care Organization Compliance Plans.....	821
V.	Practical Issues in Developing and Implementing a Compliance Program.....	822
A.	Selecting a Compliance Officer.....	822
B.	Developing a Corporate Compliance Program.....	823
C.	Education and Training.....	824
D.	Budgeting.....	825
E.	Compliance Hotline.....	826
F.	Compliance Helpline	827
G.	Auditing and Monitoring.....	827
1.	Attorney-Client Privilege.....	827
2.	External/Expert Reviews	829
3.	Expert Findings	829
4.	Types of Reviews.....	829
5.	Disclosure Obligations and Repayments.....	829
H.	Compliance Developments at the State Level	832
I.	Evolving Compliance Program Standards	834
VI.	Conclusion	834
Chapter 8	Potential Liabilities for Directors and Officers of Health Care Organizations	837
I.	Introduction.....	839
II.	Responsibilities of Directors and Officers	843
A.	Criminal Liability	843
1.	General Rule.....	843
2.	Responsible-Corporate-Officer Doctrine.....	851
B.	Civil Liability.....	856
1.	Fiduciary Responsibilities and Duties	857
a.	Duty of Loyalty	857
i.	Good Faith.....	858
ii.	Fairness (No Conflicts).....	859
iii.	Usurping Corporate Opportunity	860
b.	Duty of Care.....	861

c.	Duty of Candor.....	861
d.	Duties of Nondirector Officers.....	862
e.	Other Types of Exposure.....	863
2.	Limitations on the Liability of Directors and Officers.....	865
a.	Business Judgment Rule.....	865
b.	Statutory and Corporate Measures to Reduce Directors’ and Officers’ Liability.....	868
c.	Indemnification and Insurance.....	869
C.	The Sarbanes-Oxley Act and Related Developments.....	871
D.	Impact of Increased FCPA Enforcement on Directors and Officers of Pharmaceutical Companies.....	875
E.	Increased Antitrust Scrutiny of the Health Care Industry.....	879
F.	Impact of Health Care Reform on Health Care Fraud and Abuse Enforcement.....	883
III.	Litigation Against Officers and Directors.....	887
A.	Shareholder Derivative Actions.....	887
1.	Shareholder Derivative Actions in General.....	887
2.	Presuit Demand Requirements.....	888
3.	Other Requirements for Derivative Actions.....	890
B.	Class Actions.....	890
1.	Class Action Requirements.....	891
2.	Class Not Limited to Shareholders.....	892
3.	The Private Securities Litigation Reform Act and the Securities Litigation Uniform Standards Act.....	893
C.	The <i>Caremark</i> Decision.....	895
1.	Background of the Case.....	895
2.	The Court’s Decision.....	897
a.	Board’s Duty of Care Responsibilities.....	897
b.	Appropriate Information Gathering and Reporting Systems.....	899
D.	The Columbia/HCA Litigation.....	900
1.	Columbia/HCA Operations and Government Investigations.....	901
2.	Shareholders’ Allegations in <i>McCall v. Scott</i>	903
3.	Defendants’ Response.....	906
4.	The Magistrate’s Report and District Court Decision.....	906
a.	The Test Under Delaware Law.....	907
b.	Applying the Test to the Facts in <i>McCall</i>	908
i.	Improper Actions by Defendants.....	908
ii.	The “Red Flag” Theory.....	908
5.	The Appellate Court Decisions.....	910
a.	The Legal Standards Used.....	911
b.	Analysis of the Facts.....	914
c.	<i>McCall</i> and the <i>Abbott Laboratories</i> Case.....	916
6.	Implications of the Columbia/HCA and <i>Abbott Laboratories</i> Decisions.....	919
a.	The Sixth Circuit Decision in <i>McCall</i>	919
b.	Other Developments Relating to Presuit Demand.....	922
E.	<i>Stone v. Ritter</i> —Upholding the <i>Caremark</i> Standard for Director Liability.....	922
F.	<i>Spitzer v. Abdelhak</i>	924
1.	Background of the Case.....	924
2.	The Court’s Decision.....	925

IV. Corporate Compliance	927
A. U.S. Sentencing Guidelines	928
1. Advantages of Compliance Programs	928
2. Compliance Programs Must Be “Effective”	929
3. Concerns Raised by Compliance Programs	937
B. Compliance Program Guidance From the Department of Health and Human Services	938
1. Seven Basic Elements	939
2. Specific References to <i>Caremark</i>	940
3. Director and Officer Responsibilities for Compliance	941
a. Establishing a Compliance Program	941
b. Continuing Compliance Responsibilities	941
C. SEC/DOJ Guidance on Compliance Programs	943
D. Additional Guidance for Directors	944
V. Recommendations to Reduce Exposure	944
Chapter 9 The Past, Present, and Future of the Anti-Kickback Statute: A Practical History	951
I. Introduction: That Can’t Be Illegal ... Can It?	952
A. “The Story You Are About to Hear Is True. The Names Have Been Changed ...”	952
B. There’s No Business Like the Health Business: A Brief Introduction to the Anti-Kickback Statute	954
II. The Anti-Kickback Statute in the Twentieth Century: An Idiosyncratic Chronology of Major Developments	957
A. A Not-So-Long Time Ago, in a Congress Not So Far Away: A Very Condensed Summary of the Legislative Origins of the Anti-Kickback Statute	957
B. A Thin Line: The First “Special Fraud Alerts” and the Expansion of the Kickback Concept in the New Health Care Economy	960
C. In a Kickback State of Mind: Judicial Evolution of the Intent Standard	965
D. There Is Safety in Harbors ... Sometimes: The Evolution and Role of the Safe Harbor Regulations (and the Statutory Exceptions)	975
E. A Little Friendly Advice: The Rise and Role of OIG Advisory Opinions	986
F. “I’ll Take Potpourri for \$200”: A Miscellany of Other Sources of OIG Guidance	992
G. An Interim Summation: Key Points to Remember About the Anti- Kickback Statute	994
III. A Brief Sidebar: What’s the Difference Between the Stark Law and the Anti-Kickback Statute?	996
IV. Assembling the Pieces: A Practical Framework for Anti-Kickback Statute Analysis	1000
A. Does the Proposed Arrangement Involve Federal Health Care Program Business?	1000
1. The Threshold Question: Are There Potential Referrals of Federal Health Care Program Patients Involved?	1000
2. But What About “Private-Pay-Only” Deals?	1002
B. Why Is the Analysis Being Done?	1003
C. What Factors Are Relevant to the Analysis (Besides the Law)?	1005

D. Does the Arrangement Fit Within (or Come Close to) a Safe Harbor?	1007
E. Are There Relevant Advisory Opinions?	1010
F. Should You Get an Advisory Opinion?	1011
V. Another Sidebar: The Anti-Kickback Statute and the False Claims Act	1012
VI. The Anti-Kickback Statute in the Twenty-First Century: The Good, the Bad, and the Highly Uncertain	1014
Chapter 10 Controlling Fraud, Waste, and Abuse in the Medicare Part D Program	1019
I. Introduction	1022
II. Compliance Programs for Medicare Part D Plans	1027
A. Overview of Mandatory Compliance Program	1029
B. Sponsor Accountability for and Oversight of FDRs	1029
C. The Elements of an Effective Compliance Program	1031
1. Written Policies and Procedures and Standards of Conduct	1031
2. Compliance Officer, Compliance Committee, and High-Level Oversight	1031
3. Effective Training and Education	1034
4. Effective Lines of Communication	1034
5. Well-Publicized Disciplinary Standards	1034
6. Effective System for Routine Monitoring, Auditing, and Identification of Compliance Risks	1034
7. Procedures and System for Prompt Response to Compliance Issues	1036
III. Part D Regulatory Requirements Aimed at Addressing Significant FWA Risk	1036
A. Sales and Marketing Practices	1036
1. Broker and Sales Agent Conduct in Marketing to and Enrolling Beneficiaries	1038
2. Presenting Accurate Information About Medicare Part D Plans	1041
3. Other Improper Sales and Marketing Practices	1041
4. Communications by Pharmacies and Other Providers to Beneficiaries About Medicare Part D Plans	1042
B. Formulary Development and Maintenance	1043
C. Data Reporting Requirements	1046
D. Overutilization and Waste	1048
E. Return and Reporting of Overpayments	1051
F. Coverage Gap Discount Program	1052
G. Prescription Transfers and Automatic Refills	1053
H. Preferred Pharmacy Networks	1054
IV. Oversight, Monitoring, and Auditing	1055
A. Sponsor	1055
B. CMS	1056
1. CMS Audits	1057
2. Data Analysis and Validation	1059
3. Complaint Monitoring	1061
4. The Part D RAC Program	1061
5. Marketing Surveillance	1062
C. OIG	1063

1.	Part D Work Plan Study Results	1064
a.	Implementation of Required Programs to Deter FWA.....	1064
b.	Medicare Drug Plan Sponsors' Identification of Potential Fraud and Abuse.....	1065
c.	Medicare Prescription Drug Sponsors' Training on FWA.....	1065
d.	Bid Submission by Part D Sponsors	1066
e.	Disenrollment of Deceased Beneficiaries	1066
f.	Reconciliation Payments for 2006 and 2007.....	1067
g.	Medicare Drug Integrity Contractors' Detection of Fraud and Abuse	1067
h.	E-Prescribing in Part D	1068
i.	Medicare Prescription Drug Plans Formulary Changes	1068
j.	Beneficiaries Remain Vulnerable to Sales Agents' Marketing of Medicare Advantage Plans	1068
k.	Invalid Prescriber Identifiers on Medicare Part D Drug Claims	1069
l.	Medicare Part D—Prescription Drug Event Reconciliation Process	1069
m.	Reviews of Less-Than-Effective Drugs in the Medicare Part D Program.....	1070
n.	Concerns With Rebates in the Medicare Part D Program	1071
o.	Review of Erectile Dysfunction Drugs in the Medicare Part D Program.....	1072
p.	Review of CMS Audits of Sponsors' Financial Records.....	1072
q.	Audits of Medicare Prescription Drug Plan Sponsors by CMS	1073
r.	Review of Excluded Providers in the Medicare Part D Program.....	1074
s.	Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents and Ensuring That Medicare Part D Reimbursement Is Limited to Drugs Provided for Medically Accepted Indications.....	1074
t.	Retail Pharmacies with Questionable Part D Billing	1076
u.	Medicare Advantage Organizations' Identification of Potential Fraud and Abuse	1076
v.	Medicare Could Be Paying Twice for Prescription Drugs for Beneficiaries in Hospice Care.....	1077
w.	Inappropriate Medicare Part D Payments for Schedule II Drugs Billed as Refills	1078
x.	MEDIC Benefit Integrity Activities in Medicare Parts C and D.....	1078
y.	Gaps in Oversight of Conflicts of Interest in Medicare Prescription Drug Decisions.....	1079
2.	2013 Work Plan	1080
a.	Planned Studies and Audits Related to Accuracy of Data Submitted by Sponsors to CMS.....	1080
i.	Sponsors' Bid Proposals—Documentation of Administrative Costs	1080

ii.	Sponsors' Bid Proposals—Documentation of Investment Income	1080
iii.	Drug Payments—Drugs Dispensed Through Retail Pharmacies With Discount Generic Programs	1080
iv.	Prescription Drug Event Data—Data Submitted for Incarcerated Individuals	1080
v.	Reconciliation of Payments to Sponsors—Discrepancies Between Negotiated and Actual Rebates	1081
vi.	Coverage Gap—Quality of Sponsor Data Used in Calculating Coverage-Gap Discounts	1081
vii.	Patient Safety and Quality of Care—Part D Drugs Approved and Registered by FDA.....	1081
viii.	Coverage Gap—Accuracy of Sponsors' Tracking of True Out-of-Pocket Costs	1081
b.	Planned Studies and Audits Addressing Oversight of the Part D Program by CMS and Sponsors	1081
i.	Reconciliation of Payments to Sponsors—Reopening Final Payment Determinations.....	1081
ii.	Program Integrity—Voluntary Reporting of FWA by Plan Sponsors.....	1082
iii.	Pharmacy Benefit Managers—Part D Sponsors' Oversight of Pharmacy Benefit Managers' Administration of Plan Benefits.....	1082
c.	Planned Studies and Audits Regarding Potentially Erroneous Payments for Inappropriate Claims	1082
i.	Drug Payments—Medicare Part D Claims Duplicated in Part A and Part B	1082
ii.	Drug Payments—Characteristics Associated With Atypically High Billing	1082
iii.	Drug Payments—Questionable Claims for HIV Drugs	1082
d.	Planned Studies and Audits Regarding Compliance With Part D Program Requirements.....	1083
i.	Information Systems—Supporting Systems at Small- and Medium-Size Plans and Plans New to Medicare.....	1083
e.	Planned Studies and Audits Related to the Cost of the Part D Program.....	1083
i.	Risk Sharing and Risk Corridors—Savings Potential of Adjusting Risk Corridors	1083
ii.	Program Integrity—Beneficiary Use of Manufacturer Copayment Coupons	1083
D.	OIG Sponsor Audits.....	1084
1.	OIG Review of SilverScript Internal Controls to Guard Against FWA for the Medicare Part D Program.....	1084
2.	OIG Review of Sterling Life Insurance Company's Internal Controls to Guard Against FWA for the Medicare Part D Program	1085

3.	OIG Review of Aetna, Inc., Pharmacy Audit Recoveries for Medicare Part D Drugs Dispensed in Calendar Year 2008.....	1086
4.	OIG Review of Community Insurance, Inc., Prescription Drug Events for Institutionalized Beneficiaries for Calendar Year 2008.....	1087
5.	OIG Review of United Healthcare of Wisconsin, Inc., Prescription Drug Events for Institutionalized Beneficiaries for Calendar Year 2008.....	1088
6.	OIG Review of Part D Prescription Drug Event Data for Schedule II Drugs.....	1088
E.	Patient Assistance Programs.....	1091
V.	Enforcement Actions.....	1092
A.	CMS.....	1092
B.	OIG.....	1100
C.	FTC.....	1100
D.	State Insurance Departments.....	1100
E.	False Claims Act Cases Related to Medicare Part D.....	1101
Chapter 11	Fraud and Abuse Issues Surrounding Clinical Trials.....	1105
I.	Introduction.....	1106
II.	Financial Misconduct in Clinical Research.....	1107
A.	Payment for Clinical Research.....	1107
1.	Background and General Description.....	1107
a.	Medicare Coverage for Clinical Trials and Related Costs ...	1107
i.	National Coverage Determination.....	1107
ii.	Device Trials.....	1109
b.	General Parameters for Billing Third-Party Payors for Experimental Treatment.....	1110
c.	Payments for Treatment of Research-Related Injuries: Medicare Secondary Payer Rule.....	1110
2.	Fraud and Abuse Risks Associated With Payment for Clinical Trials and Related Costs.....	1112
a.	False Claims Act Violations.....	1112
b.	Anti-Kickback Statute Violations.....	1114
c.	Stark Law Violations.....	1118
d.	Beneficiary Anti-Inducement Statute Violations.....	1119
e.	Exclusion.....	1120
f.	Foreign Corrupt Practices Act Violations.....	1121
3.	Recommendations for Compliance.....	1124
a.	Pretrial Budget Evaluation and Preparation.....	1124
b.	Research Billing Procedures.....	1124
c.	Audits.....	1125
d.	Development and Updating of Policies, Procedures, and Training.....	1125
B.	Federal Grants Management.....	1125
1.	Background and General Description.....	1125
a.	Certifications.....	1126
b.	Time-and-Effort Reporting and Salary Allocation.....	1128
c.	Allowable Costs.....	1129
d.	Cost Transfers.....	1130
e.	Subrecipient Monitoring.....	1131

2.	Fraud and Abuse Risks Associated With Mismanagement of Federal Grant Funds	1132
a.	False Claims Act Violations	1132
b.	Exclusion	1134
3.	Recommendations for Compliance	1135
III.	Misconduct in Protecting Human Subjects.....	1136
A.	Overview of Human Subject Protection Regulations	1137
1.	General Human Subject Protection	1137
a.	Informed Consent Requirements.....	1137
b.	IRB Requirements	1138
2.	Conflicts of Interest	1139
B.	Fraudulent Activities by Researchers	1142
1.	Informed Consent	1142
2.	Conflicts of Interest	1142
3.	Misrepresentation to IRBs	1143
4.	Misrepresentation to Regulatory Agencies.....	1143
C.	Recommendations for Compliance.....	1145
IV.	Research Misconduct.....	1146
A.	Description of Research Misconduct and Associated Fraud and Abuse Risks	1146
B.	Recommendations for Compliance.....	1150
V.	Conclusion	1150
Appendix Table of Contents		1151

Appendix A: Anti-Kickback Statute Materials..... (on disk)

A-1.	Anti-Kickback Statute (42 U.S.C. §1320a-7b(b))	(on disk)
A-2.	Anti-Kickback Safe Harbor Regulations (42 C.F.R. §1001.952).....	(on disk)
A-3.	Safe Harbors for Certain Electronic Prescribing and Electronic Health Records Arrangements Under the Anti-Kickback Statute (<i>effective Oct. 10, 2006</i>), 71 Fed. Reg. 45,110 (Aug. 8, 2006).....	(on disk)
A-4.	Proposed Rule: Medicare and State Health Care Programs: Fraud and Abuse; Electronic Health Records Safe Harbor Under the Anti-Kickback Statute, 78 Fed. Reg. 21,314 (Apr. 10, 2013).....	(on disk)

Appendix B: Stark Self-Referral Law Materials..... (on disk)

B-1.	Stark Self-Referral Law (42 U.S.C. §1395nn).....	(on disk)
B-2.	Stark Phase II Final Regulations (<i>effective July 26, 2004</i>), 69 Fed. Reg. 16,054, 16,126–43 (Mar. 26, 2004), <i>codified at</i> 42 C.F.R. §§411.350–361	(on disk)
B-3.	Stark Phase II Final Regulations: Interim Final Rule with Comment Period; Correcting Amendment Pertaining to Advisory Opinion Process (<i>effective July 26, 2004</i>), 69 Fed. Reg. 57,226 (Sept. 24, 2004), <i>codified at</i> 42 C.F.R. §§411.370–389	(on disk)
B-4.	Stark Phase III Final Regulations (<i>effective Dec. 4, 2007</i>), 72 Fed. Reg. 51,012 (Sept. 5, 2007)	(on disk)
B-5.	Federal Self-Referral Regulations (combined) (<i>effective Dec. 4, 2007</i>)	(on disk)

- B-6. Physicians’ Referrals to Health Care Entities With Which They Have Financial Relationships; Exceptions for Certain Electronic Prescribing and Electronic Health Records Arrangements: Final Rule (*effective Oct. 10, 2006*), 71 Fed. Reg. 45,140 (Aug. 8, 2006) (on disk)
- B-7. Delay of the Date of Applicability for Certain Provisions of Physicians’ Referrals to Health Care Entities With Which They Have Financial Relationships (Stark Phase III) (*delaying effective date for certain arrangements until Dec. 4, 2008*), 72 Fed. Reg. 64,161 (Nov. 15, 2007) (on disk)
- B-8. Physicians’ Referrals to Health Care Entities With Which They Have Financial Relationships (Stark Phase III), Correction (*effective Dec. 4, 2007*), 72 Fed. Reg. 68,075 (Dec. 4, 2007)..... (on disk)
- B-9. Proposed Revisions to Payment Policies Under the Physician Fee Schedule, and Other Part B Payment Policies for CY 2008; Proposed Revisions to the Payment Policies of Ambulance Services Under the Ambulance Fee Schedule for CY 2008; and the Proposed Elimination of the E-Prescribing Exemption for Computer-Generated Facsimile Transmissions (*proposed rule*), 72 Fed. Reg. 38,122 (July 12, 2007)..... (on disk)
- B-10. Revisions to Payment Policies Under the Physician Fee Schedule, and Other Part B Payment Policies for CY 2008; Revisions to the Payment Policies of Ambulance Services Under the Ambulance Fee Schedule for CY 2008; and the Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions (*effective January 1, 2008, except for amendments to §409.17 and §409.23, effective July 1, 2008, and amendments to §423.160, effective January 1, 2009*), 72 Fed. Reg. 66,222 (Nov. 27, 2007) (on disk)
- B-11. Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates; Proposed Changes to Disclosure of Physician Ownership in Hospitals and Physician Self-Referral Rules; Proposed Collection of Information Regarding Financial Relationships Between Hospitals and Physicians (*proposed rule*), 73 Fed. Reg. 23,528 (Apr. 30, 2008)..... (on disk)
- B-12. Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates; Payments for Graduate Medical Education in Certain Emergency Situations; Changes to Disclosure of Physician Ownership in Hospitals and Physician Self-Referral Rules; Updates to the Long-Term Care Prospective Payment System; Updates to Certain IPPS-Excluded Hospitals; and Collection of Information Regarding Financial Relationships Between Hospitals (*final rules*), 73 Fed. Reg. 48,434 (Aug. 19, 2008)..... (on disk)
- B-13. Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2009; E-Prescribing Exemption for Computer-Generated Facsimile Transmissions; and Payment for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) (*final rule with comment period*), 73 Fed. Reg. 69,726 (Nov. 19, 2008)..... (on disk)
- B-14. CMS Voluntary Self-Referral Disclosure Protocol (Sept. 23, 2010) (on disk)

B-15.	Medicare Program: Hospital Outpatient Prospective Payment System and CY 2011 Payment Rates; Ambulatory Surgical Center Payment System and CY 2011 Payment Rates; Payments to Hospitals for Graduate Medical Education Costs; Physician Self-Referral Rules and Related Changes to Provider Agreement Regulations; Payment for Certified Registered Nurse Anesthetist Services Furnished in Rural Hospitals and Critical Access Hospitals (<i>final rule with comment period; final rules; and interim final rule with comment period</i>), 75 Fed. Reg. 71,800 (Nov. 24, 2010)	(on disk)
B-16.	Medicare Program; Physician's Referrals to Health Care Entities With Which They Have Financial Relationships: Exception for Certain Electronic Health Records Arrangements (<i>proposed rule</i>), 78 Fed. Reg. 21,308 (Apr. 10, 2013)	(on disk)
Appendix C: Civil False Claims Act Materials		(on disk)
C-1.	Civil False Claims Act (31 U.S.C. §§3729–3733)	(on disk)
C-2.	Holder Memorandum: Guidance on the Use of the False Claims Act in Civil Health Care Matters, U.S. Dep't of Justice (June 3, 1998); review (Feb. 3, 1999)	(on disk)
C-3.	Thompson Memorandum: Principles of Federal Prosecution of Business Organizations, U.S. Dep't of Justice, Office of Att'y General (Jan. 20, 2003)	(on disk)
C-4.	McNulty Memorandum: Principles of Federal Prosecution of Business Organizations, U.S. Dep't of Justice (Dec. 12, 2006)	(on disk)
C-5.	Fraud Enforcement and Recovery Act (FERA), Pub. L. No. 111-21, 123 Stat. 1617 (May 20, 2009)	(on disk)
C-6.	False Claims Act, redlined to reflect amendments enacted in FERA	(on disk)
C-7.	155 CONG. REC. S4531, S4539 (Apr. 22, 2009), Sen. Kyl Remarks on FERA	(on disk)
Appendix D: Civil Monetary Penalties and Exclusion Materials		(on disk)
D-1.	Civil Monetary Penalties Statute (42 U.S.C. §1320a-7a)	(on disk)
D-2.	Table of Office of Inspector General (HHS) Program Exclusion Authorities	(on disk)
D-3.	Exclusion of Entities From Government Health Care Programs Statute (42 U.S.C. §1320a-7)	(on disk)
D-4.	Civil Monetary Penalties Regulations (42 C.F.R. Part 1003)	(on disk)
D-5.	Regulations on Exclusion of Entities From Participation in Government Health Care Programs (42 C.F.R. §§1001.101–3005)	(on disk)
Appendix E: Selected Health Care Fraud Statutes Related to Private Payer Fraud		(on disk)
E-1.	Health Care Benefit Program False Statements Statute (18 U.S.C. §1035)	(on disk)
E-2.	Health Care Fraud Statute (18 U.S.C. §1347)	(on disk)
E-3.	Federal Health Care Offense Definitions Statute (18 U.S.C. §24)	(on disk)

Appendix F: Special Fraud Alerts and Advisory Bulletins	(on disk)
F-1. Special Fraud Alert: Rental of Space in Physician Offices by Persons or Entities to Which Physicians Refer (Feb. 2000).....	(on disk)
F-2. Special Fraud Alert: Physician Liability for Certifications in the Provision of Medical Equipment and Supplies and Home Health Services (Jan. 1999).....	(on disk)
F-3. Special Fraud Alert: Fraud and Abuse in Nursing Home Arrangements With Hospices (Mar. 1998)	(on disk)
F-4. Special Fraud Alert: Fraud and Abuse in the Provision of Services in Nursing Facilities (May 1996).....	(on disk)
F-5. Special Fraud Alert: Provision of Medical Supplies to Nursing Facilities (Aug. 1995)	(on disk)
F-6. Special Fraud Alert: Home Health Fraud (June 1995).....	(on disk)
F-7. Special Fraud Alert: Arrangements for the Provision of Clinical Laboratory Services (Oct. 1994).....	(on disk)
F-8. Special Fraud Alert: Prescription Drug Marketing Schemes (Aug. 1994)	(on disk)
F-9. Special Fraud Alert: Hospital Incentives to Referring Physicians (May 1992).....	(on disk)
F-10. Special Fraud Alert: Routine Waiver of Copayments or Deductibles Under Medicare Part B (May 1991)	(on disk)
F-11. Special Fraud Alert: Joint Venture Arrangements (Aug. 1989)	(on disk)
F-12. Special Advisory Bulletin: Practices of Business Consultants (June 2001).....	(on disk)
F-13. Special Advisory Bulletin: The Patient Anti-Dumping Statute (Nov. 1999)	(on disk)
F-14. Special Advisory Bulletin: The Effect of Exclusion From Participation in Federal Health Care Programs (Sept. 1999).....	(on disk)
F-15. Special Advisory Bulletin: Gainsharing Arrangements and CMPs for Hospital Payments to Physicians to Reduce or Limit Services to Beneficiaries (July 1999)	(on disk)
F-16. Medicare Advisory Bulletin: Questionable Practices Affecting the Hospice Benefit (Oct. 1995)	(on disk)
F-17. OIG Management Advisory Report: Financial Arrangements Between Hospitals and Hospital-Based Physicians (Jan. 1991).....	(on disk)
F-18. OIG Special Advisory Bulletin: Offering Gifts and Other Inducements to Beneficiaries (Aug. 2002)	(on disk)
F-19. OIG Special Fraud Alert: Telemarketing by Durable Medical Equipment Suppliers (Mar. 2003).....	(on disk)
F-19.1 Updated Special Fraud Alert: Telemarketing by Durable Medical Equipment Suppliers (Jan. 2010).....	(on disk)
F-20. OIG Special Advisory Bulletin: Contractual Joint Ventures (Apr. 2003).....	(on disk)
F-21. OIG Special Advisory Bulletin: Patient Assistance Programs for Medicare Part D Enrollees (Nov. 2005)	(on disk)
F-22. OIG Alert: Clinical Trials and Liability Insurance (Including Self-Insurance), No-Fault Insurance, and Workers' Compensation (May 26, 2010).....	(on disk)
F-23. Special Advisory Bulletin: Average Manufacturer Price and Average Sales Price Reporting Requirements (Sept. 28, 2010).....	(on disk)
F-24. Special Fraud Alert: Physician-Owned Entities (Mar. 26, 2013).....	(on disk)

Appendix G: Advisory Opinion Materials: Anti-Kickback Statute and Stark Self-Referral Law	(on disk)
G-1. Anti-Kickback Advisory Opinion Regulations (42 C.F.R. Part 1008)	(on disk)
G-2. Topical Index (Cumulative) and Summaries of OIG Anti-Kickback Advisory Opinions: Years 2001–Aug. 20, 2013	(on disk)
G-3. Office of Inspector General Preliminary Checklist for Advisory Opinion Requests (Anti-Kickback Statute) (July 1999)	(on disk)
G-4. Stark Law Advisory Opinion Regulations (42 C.F.R. §§411.370–.389).....	(on disk)
G-5. Overview of Stark Law Advisory Opinion Process	(on disk)
G-5.1. Stark Law Advisory Opinion No. HCFA-AO-98-001 (1998).....	(on disk)
G-5.2. Stark Law Advisory Opinion No. HCFA-AO-98-002 (1998).....	(on disk)
G-5.3. Stark Law Advisory Opinion No. CMS-AO-2005-08-01 (2005).....	(on disk)
G-5.4. Stark Law Advisory Opinion No. CMS-AO-2006-01 (2006).....	(on disk)
G-5.5. Stark Law Advisory Opinion No. CMS-AO-2007-01 (2007).....	(on disk)
G-5.6. Stark Law Advisory Opinion No. CMS-AO-2008-01 (May 2008)	(on disk)
G-5.7. Stark Law Advisory Opinion No. CMS-AO-2008-02 (June 2008)	(on disk)
G-5.8. Stark Law Advisory Opinion No. CMS-AO-2010-01 (June 2010)	(on disk)
G-5.9. Stark Law Advisory Opinion No. CMS-AO-2011-01 (May 2011)	(on disk)
G-5.10 Stark Law Advisory Opinion No. CMS-AO-2013-01 (Oct. 2013)	(on disk)
G-5.11 Stark Law Advisory Opinion No. CMS-AO-2013-02 (Oct. 2013)	(on disk)
Appendix H: Office of Inspector General Self-Disclosure Protocol	(on disk)
H-1. Office of Inspector General Provider Self-Disclosure Protocol (63 Fed. Reg. 58,399–58,403 (Oct. 30, 1998))	(on disk)
H-2. Open Letter to Health Care Providers from HHS Inspector General on the Provider Self-Disclosure Protocol (Apr. 15, 2008).....	(on disk)
H-3. Open Letter to Health Care Providers from HHS Inspector General on the Provider Self-Disclosure Protocol, Refined (Mar. 15, 2009)	(on disk)
H-4. Updated OIG’s Provider Self-Disclosure Protocol (Apr. 17, 2013)	(on disk)
Appendix I: Office of Inspector General Compliance Materials and Related Industry Documents	(on disk)
I-1.1. OIG Compliance Program Guidance for Hospitals (63 Fed. Reg. 8987–8998 (Feb. 23, 1998))	(on disk)
I-1.2. OIG Supplemental Compliance Program Guidance for Hospitals (70 Fed. Reg. 4858 (Jan. 31, 2005))	(on disk)
I-2. OIG Compliance Program Guidance for Individual and Small Group Physician Practices (65 Fed. Reg. 59,434–59,452 (Oct. 5, 2000)).....	(on disk)
I-3.1. OIG Compliance Program Guidance for Pharmaceutical Manufacturers (Apr. 2003).....	(on disk)
I-3.2. PhRMA Code on Interactions With Healthcare Professionals (Jan. 2009).....	(on disk)
I-3.3. Advanced Med. Tech. Ass’n, Code of Ethics on Interactions With Health Care Professionals (Dec. 18, 2008).....	(on disk)

- I-4. Corporate Integrity Agreement Between the Office of Inspector General of the Department of Health & Human Services and Vencor, Inc. (July 2000) (on disk)
- I-5. Draft OIG Compliance Program Guidance for Recipients of PHS Research Awards (Nov. 2005) (on disk)
- I-6. Draft OIG Supplemental Compliance Program Guidance for Nursing Facilities, 74 Fed. Reg. 20,680 (Apr. 16, 2008)..... (on disk)
- I-7. OIG Supplemental Compliance Program Guidance for Nursing Facilities, 75 Fed. Reg. 56,832 (Sept. 30, 2008)..... (on disk)

Appendix J: Medicare Managed Care Materials (on disk)

- J-1. Contract with Eligible Medicare Advantage Organization for the Operation of a Medicare Advantage Coordinate Care Plan..... (on disk)
- J-2. Addendum to Medicare Managed Care Contract for the Operation of a Voluntary Medicare Prescription Drug Plan (on disk)
- J-3. Contract with Approved Entity for the Operation of a Voluntary Medicare Prescription Drug Plan..... (on disk)
- J-4. Medicare Improvements for Patients and Providers Act (MIPPA), Pub. L. No. 11-275 (July 15, 2008) (on disk)
- J-5. Revisions to the Medicare Advantage and Prescription Drug Benefit Programs, 73 Fed. Reg. 28,556 (May 16, 2008)..... (on disk)

Appendix K: Electronic Technology Materials..... (on disk)

- K-1. American Recovery and Reinvestment Act of 2009, Health Information Technology for Economic and Clinical Health Act (HITECH Act), §13001 *et seq.*, Pub. L. No. 111-05, 123 Stat. 115 (Feb. 17, 2009) (on disk)
- K-2. Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under the Health Information Technology for Economic and Clinical Health Act and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules (*HITECH final rule*), 78 Fed. Reg. 5566 (Jan. 25, 2013) (on disk)

Appendix L: ACA Materials (on disk)

- L-1. The Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (signed Mar. 23, 2010) (ACA)..... (on disk)
- L-2. Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, 124 Stat. 1029 (signed Mar. 30, 2010) (Reconciliation Act) (on disk)
- L-3. Congressional Research Service, Medicare Provisions in PPACA (P.L. 111-148) (Apr. 2010) (on disk)
- L-4. Medicare, Medicaid, and Children’s Health Insurance Programs; Additional Screening Requirements, Application Fees, Temporary Enrollment Moratoria, Payment Suspensions and Compliance Plans for Providers and Suppliers (*final rule with comment period*) (implementing ACA) 76 Fed. Reg. 5862 (Feb. 2, 2011) (on disk)

Table of Cases 1157

Index..... 1175